The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Cyclophosphamide Plus Topotecan in Children With Recurrent or Refractory Solid Tumors: A Pediatric Oncology Group Phase II Study
Abstract
PURPOSE: To determine the response rate of the combination of cyclophosphamide and topotecan in pediatric patients with recurrent or refractory malignant solid tumors. PATIENTS AND METHODS: A total of 91 pediatric patients, 83 of whom were fully assessable for response and toxicity, received cyclophosphamide (250 mg/m 2/dose) followed by topotecan (0.75 mg/m 2/dose), each given as a 30-minute infusion daily for 5 days. All patients received filgrastim (5 mcg/kg) daily until the absolute neutrophil count (ANC) was ≥ 1,500 μL after the time of the expected ANC nadir. RESULTS: A total of 307 treatment courses were given to the 83 fully assessable patients. Responses (complete response plus partial response) were seen in rhabdomyosarcoma (10 of 15 patients), Ewing’s sarcoma (six of 17 patients), and neuroblastoma (six of 13 patients). Partial responses were seen in two of 18 patients with osteosarcoma and in one patient with a Sertoli-Leydig cell tumor. Twenty-three patients had either minor responses (n = 6) or stable disease (n = 17); the median number of courses administered to patients with partial or complete response was six (range, two to 13 courses), and the median administered to those with stable disease was three (range, one to 11 courses). The toxicity of the combination was limited principally to the hematopoietic system. Of 307 courses, 163 (53%) were associated with grade 3 or 4 neutropenia, 84 (27%) with grade 3 or 4 anemia, and 136 (44%) with grade 3 or 4 thrombocytopenia. Despite the severe myelosuppression, only 34 (11%) of 307 courses were associated with grade 3 or 4 infection. Nonhematopoietic toxicity of grades ≥ 3 was rare and consisted of nausea and vomiting (two courses), perirectal mucositis (one course), transaminase elevation (one course), and hematuria (two courses). CONCLUSION: The combination of cyclophosphamide and topotecan is active in rhabdomyosarcoma, neuroblastoma, and Ewing’s sarcoma. Stabilization of disease was seen in osteosarcoma, although objective responses were rare in this disease. The therapy can be given with acceptable hematopoietic toxicity with the use of filgrastim support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGS
Liu, L. F. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.002031 · Cited by 1,811
The Current Status of Camptothecin Analogues as Antitumor Agents
Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., & Kaufmann, S. H. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.4.271 · Cited by 618
Topoisomerase Inhibitors: A Review of their Therapeutic Potential in Cancer
Sinha, B. K. (1995) · Drugs · doi:10.2165/00003495-199549010-00002 · Cited by 178
Zamboni, W. C., Stewart, C. F., Houghton, P. J., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.7.505 · Cited by 136
Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors
Kushner, B. H., Kramer, K., Meyers, P. A., Wollner, N., & Cheung, N. V. (2000) · Medical and Pediatric Oncology · Cited by 68
Blaney, S. M., Needle, M. N., Gillespie, A., Sato, J. K., Reaman, G. H., Berg, S. L., Adamson, P. C., Krailo, M., Bleyer, W. A., Poplack, D. G., et al. (1998) · PubMed · Cited by 62
Cited by
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Balamuth, N. J., & Womer, R. B. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70286-4 · Cited by 686
Ewing's Sarcoma Family of Tumors: Current Management
Bernstein, M., Kovar, H., Paulussen, M., Randall, R. L., Schuck, A., Teot, L. A., & Juergensg, H. (2006) · The Oncologist · doi:10.1634/theoncologist.11-5-503 · Cited by 520
Self-citationOverview and recent advances in the treatment of neuroblastoma
Whittle, S. B., Smith, V., Doherty, E., Zhao, S., McCarty, S., & Zage, P. E. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1285230 · Cited by 394
NCCN Guidelines Insights: Bone Cancer, Version 2.2017
Biermann, J. S., Chow, W., Reed, D. R., Lucas, D., Adkins, D. R., Agulnik, M., Benjamin, R. S., Brigman, B., Budd, G. T., Curry, W. T., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0017 · Cited by 294
Metadata
- Authors
- Saylors, R. L., Stine, K. C., Sullivan, J., Kepner, J. L., Wall, D. A., Bernstein, M. L., Harris, M. B., Hayashi, R., & Vietti for the Pediatric Oncology Group, T. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-08-01
- Volume
- 19
- Issue
- 15
- Pages
- 3463-3469
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1935226228
- Cited by
- 315
- References
- 6
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclophosphamide Plus Topotecan in Children With Recurrent or Refractory Solid Tumors: A Pediatric Oncology Group Phase II Study. https://app.cochat.ai/papers/10.1200/jco.2001.19.15.3463
- The paper
- Saylors, R. L., Stine, K. C., Sullivan, J., Kepner, J. L., Wall, D. A., Bernstein, M. L., Harris, M. B., Hayashi, R., & Vietti for the Pediatric Oncology Group, T. J. (2001). Cyclophosphamide Plus Topotecan in Children With Recurrent or Refractory Solid Tumors: A Pediatric Oncology Group Phase II Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2001.19.15.3463
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.